1. CTIM-32. FIRST-IN-CHILDREN PHASE 1 TRIAL OF INDOXIMOD-BASED CHEMO-IMMUNOTHERAPY FOR PATIENTS WITH PEDIATRIC BRAIN TUMORS: ANALYSIS OF SAFETY, TOLERABILITY, AND 5-YEAR OUTCOME. (14th November 2022) Authors: Johnson, Theodore; Pacholczyk, Rafal; Aguilera, Dolly; Al-Basheer, Ahmad; Bajaj, Manish; Bandopadhayay, Pratiti; Berrong, Zuzana; Bouffet, Eric; Castellino, Robert; Dorris, Kathleen; Eaton, Bree; Esiashvili, Natia; Foreman, Nicholas; Fridlyand, Diana; Giller, Cole; Heger, Ian; Kadom, Nadja; Kenne... Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 7 Page Start: vii68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. IMMU-04. FIRST-IN-CHILDREN PHASE 1B STUDY USING THE IDO PATHWAY INHIBITOR INDOXIMOD IN COMBINATION WITH RADIATION AND CHEMOTHERAPY FOR CHILDREN WITH NEWLY DIAGNOSED DIPG (NCT02502708, NLG2105). (1st June 2021) Authors: S. Johnson, Theodore; Pacholczyk, Rafal; Aguilera, Dolly; Al-Basheer, Ahmad; Bajaj, Manish; Berrong, Zuzana; Castellino, Robert C; Eaton, Bree R; Esiashvili, Natia; Foreman, Nicholas; Heger, Ian M; Kennedy, Eugene P; Martin, William; Ring, Eric; Sadek, Ramses F; Smith, Amy; Smith, Chris; Vaizer, ... Journal: Neuro-oncology Issue: Volume 23(2021)Supplement 1 Page Start: i27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗